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Chronic unexplained cough triggered by environmental irritants is characterized by increased
cough reflex sensitivity, which can be demonstrated by means of inhaled capsaicin. Topical
capsaicin can be used to improve non-allergic rhinitis and intestinal hypersensitivity and to
reduce neuropathic pain.
Objectives: We established whether an oral intake of natural capsaicin (chilli) could desensi-
tize the cough reflex and improve unexplained coughing.
Methods: Twenty-four patients with irritant-induced, unexplained chronic cough and 15 con-
trols were included in the study. For 4 weeks, the participants took capsules with pure capsa-
icin, and for 4 weeks, they took placebo capsules. The protocol was crossover, randomized,
and double blind. Cough sensitivity during the study was evaluated by a standardized capsaicin
inhalation cough test that assessed the capsaicin concentration required to reach two coughs
(C2) and five coughs (C5). Participants were also administered questionnaires on cough and
cough-related symptoms.
Results: Three patients withdrew before the study end, one during the active treatment
period and two during the placebo period. After treatment with capsaicin, the thresholds
for C2 were higher (improved) both in patients (p < 0.020) and in controls (p < 0.0061)
compared to after the placebo period. Among patients, the concentration needed to reach
C2 (p < 0.0004) and C5 (p < 0.0009) increased after the period with the active substance
compared to cough thresholds at baseline. The cough symptom scores improved after 4 weeks
of active treatment (p < 0.0030) compared to the baseline scores.of Respiratory Medicine and Allergology, The Sahlgrenska Academy at Gothenburg University, S-413
3423635; fax: þ46 31 417824.
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28 E. Ternesten-Hasse´us et al.Conclusion: Capsaicin powder taken orally decreased capsaicin cough sensitivity and cough
symptoms. The findings suggest a desensitization of the cough-sensitive transient receptor po-
tential vanilloid-1 (TRPV1).
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
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Chronic cough is a common problem that influences quality of
life and is associated with a psychological and social burden
[1,2]. In a substantial group of patients, there is no evident
explanation for the coughing [3], and further, inmanyof these
patients the cough is refractory to any treatment [4].
A subgroup of patients with airway complaints who report
cough and other airway symptoms from scents and chemicals
have increased capsaicin cough sensitivity levels [5]. As this
capsaicin-induced cough can be blocked by inhaled anaes-
thesia, it has been suggested that sensory nerves are involved
in thepathophysiology [6]. Consequently,wehavepreviously
proposed amechanism to increase sensitivity of the afferent
sensory nerves in patients with airway symptoms induced by
scents and chemicals, and we have further suggested using
the term sensory hyper-reactivity (SHR) to identify this
mechanism [7]. In many chronic cough patients where the
cough is labelled idiopathic or unexplained, there is a history
of sensitivity to environmental irritants such as chemicals
and perfumed products as well as increased capsaicin cough
sensitivity [1,8].
Inhaled capsaicin (8-methyl-N-vanillyl-6-nonenamide),
the pungent ingredient in chilli fruits, has long been used to
provoke coughing in a safe and dose-dependent manner
whereby the degree of the induced cough reflects the reac-
tivity of sensory C-fibres in the respiratory mucosa via the
transient receptor potential vanilloid-1 (TRPV1) [9]. The
inhalationof capsaicin hasbeen important in cough research,
and has demonstrated good short- and long-term reproduc-
ibility [10] as the inhaled capsaicin may be regarded as
representative of a diverse range of irritating/noxious stim-
uli that induce cough and airway irritation [11]. In chronic
cough the capsaicin cough sensitivity is increased and linked
to a cough hypersensitivity [12e14]. Inhaled capsaicin is, at
least in healthy subjects and in asthma patients, followed by
a quick and short-lasting desensitization, meaning that the
initial induced capsaicin cough is often followed by a toler-
ance tohigher doses of inhaled capsaicin.However,when the
capsaicin challenge was performed with at least one day in
between capsaicin administration, there was no evidence of
desensitization or evidence that desensitization extends
over longer periods [15,16].
In non-allergic rhinitis, treatment with topical capsaicin
may reduce symptoms and nasal hyper-reactivity. To sup-
port this supposition, a recent study among such patients
not only found reduced symptoms and reduced levels of
nasal hyper-reactivity but also found an overexpression of
TRPV1 in the nasal mucosa and increased substance P (SP)
levels in nasal secretions [17]. The authors suggest that the
topical capsaicin treatment ablated the TRPV1-SP noci-
ceptive signalling pathway in the nasal mucosa.TRPV1 is, in addition to being involved in cough and
rhinitis, a major player in pain and pain sensitivity, and
therefore, there is increasing interest in the development
of TRPV1 antagonists, mainly for neuropathic pain disorders
but also for cough treatment [18e20]. For decades, a va-
riety of topical products (creams, gels, and patches) with
capsaicin or capsaicinoids as a major active component
have been available as pain relievers. More recently,
developed products with larger doses of topical capsaicin
have proved to be more effective in reducing neuropathic
and chronic pain and in providing long-lasting analgesia
with rapid onset [21]. The theoretical explanation for the
ability of topical capsaicin to relieve pain is that it
defunctionalizes or desensitizes the sensory C-fibres [19].
TRPV1 is widely represented in the gastrointestinal sys-
tem. There is a connection between these receptors and
chronic symptoms such as irritable bowel syndrome (IBS) as
evidenced by the increased expression of TRPV1 [22].
Several studies have shown an improvement in IBS and gut
pain sensitivity after the regular intake of capsaicin powder
[23e25]. The ingestion of capsaicin from a spicy diet was
previously thought to be related to an increase in gastro-
intestinal cancer, but more recent research has indicated a
role of pure capsaicin in the prevention and treatment of
cancer, though the human metabolism of capsaicin is still
largely unknown [26].
In concordance with topical capsaicin having previously
been known to reduce rhinitis, neuropathic pain, and in-
testinal sensitivity, we aim to assess whether capsaicin,
taken orally on a regular basis, reduces cough symptoms
and capsaicin cough sensitivity.Methods
Patients
The medical staff at the Asthma and Allergy Clinic at
Sahlgrenska University Hospital, Gothenburg, Sweden were
informed of the study by a written letter that asked them to
contact our study nurse when meeting a patient who
seemed suitable for the study. Twenty-four non-smoking
patients (22 women and two men) who had chronic, unex-
plained cough and who claimed sensitivity to environmental
irritants such as chemicals and perfumed products were
consecutively selected from the clinic during the first
months of 2013. A nurse contacted the participants by
telephone and asked them to participate in the study.
To be included in the study, participants needed to have
a history of at least one year of cough induced by envi-
ronmental irritants and to have earlier reached the limit for
a positive capsaicin inhalation cough test [27]. Cough
24 patients and 15 controls
assessed for eligibility and 
randomized to
12 patients and 7 controls assigned to group
B and taking placebo for 4 weeks
12 patients and 8 controls assigned to group
A and taking capsaicin for 4 weeks
1 patient lost during the first
week due to possible adverse
events
2 patients lost after 4 weeks
due to possible adverse
events, 1 performed the
second capsaicin provocation
11 patients and 8 controls assigned to 
group A changed to placebo after 4 
weeks
10 patients and 7 controls assigned to 
group B changed to capsaicin after 4 
weeks
11 patients and 8 controls assigned to 
group A analysed for the study outcome
after 8 weeks
10 patients and 7 controls assigned to 
group B analysed for the study outcome
after 8 weeks
Group A Group B
Figure 1 Flow chart of the study.
Reduction of chronic cough 29should be the patient’s major problem, but the individual
could also present with other airway symptoms from envi-
ronmental irritants. The patients were administered ques-
tionnaires on airway symptoms in response to
environmental irritants [1], and all reported cough due to
such irritants.
Exclusion criteria included any other pulmonary or res-
piratory illness such as chronic rhino-sinusitis, allergy,
asthma, eosinophilic bronchitis, chronic obstructive pul-
monary disease or interstitial lung disease. A negative skin
prick test result for ten of the most common respiratory
allergens in Sweden was mandatory as was a negative
methacholine test in accordance with international guide-
lines [28]. Furthermore, any spirometric reversibility or
variability in lung function, a diagnosis of gastro-
oesophageal reflux, the use of angiotensin-converting
enzyme inhibitors or any medication for gastro-
oesophageal reflux, any known cardiovascular disease,
current pregnancy or breastfeeding were all criteria for
exclusion from the study.
All patients had a history (though not systematically
tested) of using a variety of asthma and cough medications
without any major improvement.Control group
The control group consisted of 15 non-smoking, subjec-
tively healthy individuals: 13 women and two men. They
were recruited among friends, relatives, and crew at theclinic and were screened using questions on cough and
airway symptoms in response to environmental irritants [1].
None had a history of any respiratory disease such as
asthma, allergies or cough in response to environmental
irritants, none were taking any medication for the airways
or for gastro-oesophageal reflux, and none were pregnant
or breastfeeding at the time of study.
Written informed consent was obtained from all partic-
ipants after they were provided with information about the
study in both verbal and written format. The Regional
Ethics Review Board of Gothenburg, Sweden, approved the
study.Study design
Each participant visited the clinic three times during an 8-
week study period: before the start of the study and after
4 and 8 weeks. At each visit, cough sensitivity was
assessed by a standardized capsaicin inhalation cough test
using the threshold method [29], following the recom-
mendations in the European Respiratory Societies (ERS)
guidelines [30]. They also answered questionnaires
relating to cough and completed a daily “patient cough
and symptom diary”. Fig. 1 presents a flow chart of the
trial, and Table 1 presents a description of the procedures
for each visit.
The protocol was crossover, randomized, and double
blind. A nurse at the allergy clinic, not working with the
study and not informed of the study design, conducted the
Table 1 Description of study procedures.
Visit no/Week e 1 2 3
1 week
Before
Baseline Week 4 Week 8
Study information
and consent to
participation
X
Inclusion/exclusion
criteria
X
Demographics and
participants’
characteristics
X
Randomization to
Group Aa or Group Bb
X
Capsaicin test X X X
Hull cough questionnaire X X X
Spirometry X X X
Cough and symptom diaryc X X X X
a Baseline to Week 2: capsaicin 0.4 mg 1  2 capsules; Week 2
to Week 4: capsaicin 0.4 mg 2  2 capsules; Week 4 to Week 6:
placebo 1  2 capsules; Week 6 to Week 8: placebo 2  2
capsules.
b Baseline to Week 2: placebo 1  2 capsules; Week 2 to Week
4: placebo 2  2 capsules; Week 4 to Week 6: capsaicin 0.4 mg
1  2 capsules; Week 6 to Week 8: capsaicin 0.4 mg 2  2
capsules.
c Cough and symptom scores were filled out every day
throughout the study, and also 1 week before the study.
30 E. Ternesten-Hasse´us et al.randomization via a lottery with blinded lottery tickets
marked A or B. The participants were then randomly
assigned to either Group A, which received four weeks of
active treatment, or Group B, which received four weeks of
a placebo. At the end of the four-week period, the groups
were changed. That is, Group A received the placebo for
four weeks, and Group B received the active treatment.
The transparent capsules were made from gelatin and
contained a white powder of either placebo (a pure crys-
talline cellulose powder) or 0.4 mg pure capsaicin powder
from natural chilli fruits (8-methyl-N-vanillyl-6-
nonenamide, M2028-1G; SigmaeAldrich, Sweden AB,
Stockholm). For the first two weeks of the active treatment
period, the participants were given one capsule with 0.4 mg
pure capsaicin twice daily, and for the following two weeks,
they were given two capsules with 0.4 mg pure capsaicin
twice daily. During the placebo period, they started taking
one capsule twice daily, and after two weeks, they took
two capsules twice daily in the same manner. Participants
and research staff were blind to treatment allocation
because all capsules were identical in appearance. The
participants were instructed to only take the capsules
together with food.Capsaicin provocation
A stock solution of capsaicin (M2028; SigmaeAldrich,
Sweden AB, Stockholm) [1 mmol/L in ethanol (99.5%)] was
prepared and then dissolved in 0.9% saline to provide astock solution of 500 mmol/L capsaicin. Fresh serial di-
lutions were prepared from the stock solution using saline
diluent to double the concentrations from 0.49 to
500 mmol/L. Capsaicin solutions were administered from a
compressed airedriven side-stream nebulizer (MedicAid
Pro, Sussex, UK) controlled by an aerosol provocation
system (APS version 5.02 software, Viasys Healthcare
GmbH, Hoechberg, Germany). Double concentrations were
given at 1-min intervals, and the concentration of capsa-
icin causing two (C2) and five (C5) coughs during the 1-
min period between each dose was registered [29]. The
participants were not informed that the cough thresholds
were the endpoints of the provocation. A value of
1000 mmol/L capsaicin was assigned if C2 and/or C5 values
were >500 mmol/L.
The cough thresholds of the study participants were
registered manually during the provocation. Cough was
defined as the characteristic sound that follows a forced
expiratory effort against a closed glottis and was distin-
guished from other sounds, such as clearing the throat [31],
by a discretionary decision of the investigator upon obser-
vation of the subjects.
In all participants, the forced expiratory volume during
1 s (FEV1) was measured using a MasterScope (version 4.67
software; Viasys Healthcare GmbH, Hoechberg, Germany)
before and after each completed capsaicin provocation.
The participants used a nose clip during the spirometry, and
the higher of two values was recorded. The total time for
each visit was approximately 45 min. In the event of a
respiratory infection during the past month, the capsaicin
provocation was not conducted. All medication was with-
held for at last 4 h before any test. Long-acting broncho-
dilators were withheld for at least 48 h and antihistamines
were suspended for at least 5 days before the capsaicin
inhalation challenge.Symptom registration and questionnaire
Each evening during the week before the study start and for
the following 8 study weeks, the patients completed a
symptom diary wherein they scored their cough symptoms
on a scale of 0e3, with 0 indicating no coughing and 3
indicating intense symptoms. The sum of cough symptom
scores for each week was analysed. The maximum weekly
score was 21.
As safety parameters, each evening, the participants
also completed a diary of symptoms regarded as having a
possible relation to the study on a scale of 0e3, with
0 indicating no coughing and 3 indicating intense symp-
toms. At each visit, the study nurse interviewed the par-
ticipants regarding their general condition, respiratory
infections, and any possible side effects and furthermore,
the patients had the possibility to comment in their own
words on their condition and any suspected adverse
events.
At each visit, the patients and the control subjects
answered the Swedish version of the Hull cough question-
naire [1,32], which consists of 14 items. The unweighted
sum of all 14 items makes up the subject’s total Hull cough
score, which ranges from 1 to 70. The cut-off value 13 is
considered a normal value.
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The primary efficacy analysis in this study was the analysis
of the difference between the effects of the active treat-
ment and the placebo treatment with respect to variables
C2log and C5log. Both treatments were performed on both
study patients and healthy controls. The effect of the
active and the placebo treatment alone and the carry-over
effect were considered as complementary analyses and
were reported as secondary efficacy analyses.
The secondary efficacy analyses were furthermore
change in Hull cough questionnaire after active treatment
compared to before active treatment.
Predefined safety analyses
All symptoms related to cough and other respiratory con-
cerns were recorded by the study patients in a diary one
week prior to the first treatment and during the 8-week
treatment period on a scale of 0e3, with 0 indicating no
symptoms and 3 indicating intense symptoms. They were
coded by a medical expert and categorized as follows:
 Prior symptoms, i.e., all symptoms that started prior to
the first dose taken in the study
 Active treatment emergent symptoms, i.e., all symp-
toms that started at the time the first active dose was
taken or during the period the patient was receiving
active treatment
 Placebo treatment emergent symptoms, i.e., all symp-
toms that started at the time the first placebo dose was
taken or during the period the patient was receiving the
placebo treatmentStatistical analysis
All randomized subjects with at least one follow-up value
on the capsaicin test were included in the Intent-to-Treat
(ITT) population. A drop-out analysis between subjects
excluded from the ITT population versus the ones included
was intended on all available baseline data to evaluate
whether there were any significant differences. All enrolled
subjects who received at least one completed dose of the
randomized capsaicin/placebo treatment were included in
the safety population. For the primary and secondary an-
alyses of the capsaicin values, logarithmic values of the
capsaicin levels were analysed due to the exponential na-
ture of capsaicin doses.
The effect of Active (A) versus Placebo (B) on C2log and
C5log was defined as the difference of values at the end of
the treatments, i.e., week 4 value and week 8 value, A-B
for both the AB and the BA group. The effect of A on log C2
and log C5 was defined as the difference of week 4-baseline
for the AB group and week 8-week 4 for the BA group. The
effect of B was defined as the difference of week 4-baseline
for the BA group. The Wilcoxon signed rank test was used
for comparing such paired data.
The carry-over effect that is expected in this study was
investigated by calculating the average of the values at the
end of the active treatment and the placebo treatment forboth AB and BA groups and then the difference between the
groups was tested using the ManneWhitney U-test.
For comparing the two groups, Fisher’s exact test was
used for dichotomous variables, and the ManneWhitney U-
test was used for continuous variables. All tests were
two-tailed, and the results were considered significant if
p < 0.05. Data were analysed using SAS version 9.2 (Cary,
NC, USA).Results
Three of the original 24 patients, one man and two women,
were not available for analyses. One patient assigned to
group A withdrew after been treated with capsaicin for one
week due to complaints of reflux and stomach pain. He was
only administered capsaicin provocation at one opportunity
(baseline) and was not included in the ITT or safety
analyses.
Two patients belonging to group B (starting with the
placebo) withdrew after four weeks of treatment with the
placebo. Both patients complained of gastrointestinal
symptoms such as stomach pain and reflux as well as more
general symptoms such as headache and fatigue. As one of
these two patients agreed to a second capsaicin provoca-
tion, her results were included in the final analyses. Thus,
22 patients were eligible for inclusion in both the ITT and
safety analyses.
With only two patients excluded from the ITT and safety
analyses it was not possibly to analysis whether there were
any differences in baseline data compared to the ITT group.
None of the participants reported any respiratory
infection, and thus, all capsaicin provocation could be
completed.Sample size calculation
The sample size calculations for logC2 and logC5 given the
results obtained in the study are described by following
sentences:
For LogC2
In order to reach the power of 0.80 with mean difference
between the Active-Placebo treatment of 0.590 and stan-
dard deviation for mean difference of 0.885, with two-
tailed Wilcoxon Signed Rank test, alphaZ 0.05, 22 patients
are needed to be included in the study.
For LogC5
In order to reach the power of 0.80 with mean difference
between the Active-Placebo treatment of 0.425 and stan-
dard deviation for mean difference of 0.911, with two-
tailed Wilcoxon Signed Rank test, alphaZ 0.05, 41 patients
are needed to be included in the study.Power calculation
The power calculation for logC5 given the results obtained
in the study are described by following sentences:
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Including 22 patients in the study with mean difference
between the Active-Placebo treatment of 0.425 and stan-
dard deviation for mean difference of 0.911, a power of
0.50 will be reached with two-tailed Wilcoxon Signed Rank
test, alpha Z 0.05.
Hence, the power calculation revealed that the number
of patients included in the study was not sufficient to have
enough power to reach the statistical difference for LogC5.
Baseline values
Participants’ characteristics at the baseline visit are pre-
sented in Table 2. Spirometric values were within normal
limits at the start point and did not change significantly
from baseline during the study (data not shown). At base-
line, the patients and the controls showed a dose-Table 2 Participants’ characteristics at baseline (ITT populatio
Characteristics at baseline Study pati
Age 52.0 (12.2
55.0 (21.0
Gender
Male 2 (9.5%)
Female 20 (90.9%)
Cough induced by:
Environmental irritants 21 (100.0%
Cold air 12 (54.5%)
Coughing
Daily 16 (72.7%)
Weekly 6 (27.3%)
Duration of symptoms (years) 16.6 (11.3
15.5 (2.5;
Smoking history
Never smoked 15 (68.2%)
Ex-smoker 7 (31.8%)
Pack-yearsa 3.7 (8.3)
0.0 (0; 34
BMI (kg/m2) 25.4 (6.3)
24.7 (18.1
Drugs at time of study
Short-acting b2 agonist 1 (5%)
Inhaled corticosteroids þ long-acting b2 agonist 1 (5%)
Short-acting anticholinergic 2 (9%)
Nasal steroids 2 (9%)
Antihistamines 1 (5%)
Spirometry
FEV1 (%predicted) 104.6 (14.
101.1 (76.
Hull cough questionnaire 26.5 (16.7
28.0 (1.0;
n Z 21
Capsaicin cough thresholds at baseline
C2 (mM capsaicin) 2.2 (4.4)
1.0 (0.5; 7
C5 (mM capsaicin) 5.2 (4.4)
3.9 (0.5; 1
For categorical variables n (%) is presented. For continuous variables
between groups Fisher’s exact test was used for dichotomous variables
a Values also include participants who had never smoked (i.e. packdependent cough reaction, that is, coughing increased
with increasing capsaicin concentrations.
Primary analyses of efficacy
Effect of active substance versus placebo
Differences in logarithm capsaicin cough thresholds be-
tween the active substance (capsaicin) and the placebo are
presented in Table 3.
Secondary analyses of efficacy
Effect of active substance versus compared to baseline
The effects of the active substance (capsaicin) on capsaicin
cough thresholds (logarithm values) compared to baseline
are presented in Table 3.n).
ents (n Z 22) Healthy controls (n Z 15) p-Value
) 51.0 (13.7) 0.90
; 66.0) 55.0 (27.0; 69.0)
1.00
2 (13.3%)
13 (86.7%)
) 0
0
0
0
) 0 <0.0001
50.0)
15 (100.0%)
0 (0.0%) 0.033
)
0
; 48.6)
22.7 (2.7)
22.6 (18.9; 27.5)
0.095
7)
3; 130.0)
108.7 (11.2)107 (89.1; 126.0) 0.42
)
56.0)
1.8 (2.2)
1.0 (0.0; 6.0)
<0.0001
.8)
250.3 (396.9)
31.2 (1.0; 1000)
<0.0001
5.6)
604.4 (464.6)
1000 (3.9; 1000)
<0.0001
Mean (SD)/Median (Min; Max)/n Z is presented. For comparison
and the ManneWhitney U-test was used for continuous variables.
-years 0).
Table 3 Effects of treatment (ITT population).
Variables Study patients Healthy controls
Mean (SD) Median
(min; max)
p-Value within
group
Mean (SD) Median
(min; max)
p-Value within
group
Primary Analysis:
Effect of active vs placebo
Logarithm values
Difference Active-
Placebo C2log
(mM capsaicin)
0.6 (0.9)
0.7 (0.7; 2.1)
n Z 21
0.020 1.2 (1.4)
0.7 (0.7; 4.2)
n Z 15
0.0061
Difference Active-
Placebo C5log
(mM capsaicin)
0.4 (0.9)
0.0 (0.7; 2.8)
n Z 21
0.063 0.4 (2.2)
0.0 (4.9; 4.2)
n Z 15
0.52
Secondary analysis:
Effect of active substance
Logarithm values compared to baseline
Capsaicin effect C2log (mM capsaicin) 1.0 (0.9)
0.7 (0.7; 2.1)
n Z 21
0.0004 0.6 (1.5)
0.0 (1.4; 4.2)
n Z 15
0.30
Capsaicin effect C5log
(mM capsaicin)
0.8 (0.9)
0.7 (0.7; 2.8)
n Z 21
0.0009 0.4 (2.2)
0.0 (4.9; 4.2)
n Z 15
0.58
Effect of placebo
Logarithm values compared to baseline
Placebo effect C2log (mM capsaicin) 0.1 (0.6)
0.0 (0.7; 0.7)
n Z 11
1.00 0.4 (1.4)
0.0 (1.4; 2.8)
n Z 7
0.69
Placebo effect C5log (mM capsaicin) 0.3 (1.2)
0.7 (1.4; 2.1)
n Z 11
0.59 0.8 (1.9)
0.7 (1.4; 4.9)
n Z 7
0.50
Hull cough questionnaire
Change in Hull questionnaire after the
active treatment period
5.4 (8.2)
4.0 (24.0; 5.0)
n Z 19
0.008 0.7 (2.6)
0.0 (3.0; 6.0)
n Z 15
0.38
For continuous variables Mean (SD)/Median (Min; Max)/nZ is presented. For comparison within groups the Wilcoxon signed rank test was
used.
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The effects of the placebo on capsaicin cough thresholds
are presented in Table 3. Changes in cough thresholds after
four weeks of taking a placebo were analysed in 10 patients
and seven controls (group B) (not having taken any active
substance).
The Hull cough questionnaire
We compared differences in Hull cough questionnaire after
4 weeks of capsaicin treatment to corresponding values
before the active treatment period (Table 3).
Carryover effects
The possibility of any carryover effect was analysed to see
whether the active substance influenced the results
following from the placebo, but no such effects were
found. The mean differences of cough thresholds after a 4-
week period with placebo did not differ between group A
and group B, indicating that there was no prolonged effect
in the group that received the active substance first (group
A) (data not shown).Analyses of patient cough symptom score
We compared the weekly cough score (1e21) the week
before the start of active capsaicin treatment with the last
week of this period. There was a significant change in cough
score (less coughing) (p < 0.0030) after the capsaicin
treatment but not after the placebo treatment. Individual
values for cough symptoms are presented in Fig. 2 and an
overview in Table 4.Adverse events
The most common symptoms in the patients’ diaries
recorded the week before study start, the last week of the
capsaicin treatment period, and the last week of the pla-
cebo period, respectively, are shown in Table 4. The pa-
tients scored their symptoms on a scale from 0 to 3 each
evening during the study. In Table 4, scoring 1 is regarded as
a mild symptom, 2 indicates a moderate symptom and 3
indicates a severe symptom. There was no evident pattern
Figure 2 Sum of cough symptom scores (0e21) in 21 patients
during the week prior to the start of the study and the last
week of the capsaicin and placebo treatments, respectively.
34 E. Ternesten-Hasse´us et al.in the symptom scoring to indicate differences between the
scores during the capsaicin and the placebo treatments.
Among the control subjects, no or few adverse events
were consistently reported.Discussion
The main findings in this study are that the regular oral
intake of pure capsaicin from chilli fruits decreased
capsaicin cough sensitivity and improved cough symptoms
and cough scores in chronic cough patients. Moreover, the
capsaicin supplement in the present study was well toler-
ated and exhibited few side effects.
At baseline, cough patients had increased capsaicin
cough sensitivity compared to the control subjects, which isTable 4 Number of patients that at least once, during one we
symptom.
Symptoms Mild or moderate symptoms Se
Week before
baseline
Last week of
active treatment
Last week of
placebo trea
n Z 24 n Z 22 n Z 23
Any symptoms 24 (100.0%) 21 (95.5%) 23 (100.0%)
Cough 23 (95.8%) 17 (77.3%) 20 (87.0%)
Hoarseness 14 (58.3%) 12 (54.5%) 14 (60.9%)
Throat irritation 17 (70.8%) 13 (59.1%) 16 (69.6%)
Dyspnoea 10 (41.7%) 5 (22.7%) 7 (30.4%)
Mucus 18 (75.0%) 15 (68.2%) 13 (56.5%)
Rhinitis 19 (79.2%) 14 (63.6%) 16 (69.6%)
Eye irritation 10 (41.7%) 7 (31.8%) 8 (34.8%)
Chest discomfort 9 (37.5%) 5 (22.7%) 4 (17.4%)
Diarrhoea 2 (8.3%) 4 (18.2%) 2 (8.7%)
Stomach pain 6 (25.0%) 10 (45.5%) 5 (21.7%)
Flatulence 10 (41.7%) 11 (50.0%) 9 (39.1%)
Reflux 6 (25.0%) 6 (28.6%) 4 (17.4%)
Headache 15 (62.5%) 9 (40.9%) 12 (52.2%)
For categorical variables n (%) is presented.consistent with several earlier studies [5,29,33]. However,
there was some variance in capsaicin cough reaction among
the controls even though they had no cough or other airway
symptoms indicating increased capsaicin cough sensitivity
[29]. This may have influenced the significant difference for
C2 in controls regarding capsaicin treatment versus placebo
(Table 3).
As chronic refractory cough is probably a combination of
peripheral and central mechanisms, both must be targeted
[4]. Because cough sensitivity in our study decreased after
oral supplementation with capsaicin, the proposed mech-
anism of our results is the peripheral desensitization of
airway receptors, though a central reflex desensitization
could also be involved given the known presence of TRPV1
receptors in the central nervous system [34].
The findings in the present study are consistent with
other reports regarding topical capsaicin as a desensitizer
in neuropathic pain and pain sensitivity in the gastrointes-
tinal tract [18,19,23,25,35,36], and they are also in
agreement with reports of reduced nasal symptoms from
intranasal capsaicin in non-allergic rhinitis [17]. However,
the interpretations of these earlier results are mainly based
on capsaicin treatment having a direct, local effect on
TRPV1. The present study, however, suggests that desen-
sitization could have been the result of metabolized
capsaicin entering circulation, though, at least in rats, only
low levels of capsaicin could be detected in trunk blood
after capsaicin was administered intragastrically [37].
Conversely, in rodents, systemic administration of capsaicin
was followed by desensitization of TRPV1 in the respiratory
mucosa [38]. Reflexes from the gastrointestinal tract
evoked by the orally administered capsaicin may also have
played an important role in the reduction of cough and
cough sensitivity in the present study. As there are few
publications on plasma concentrations following the
ingestion of chilli peppers, the metabolism of capsaicin isek, scored (on a scale form 1e3) a mild, moderate or severe
vere symptoms
tment
Week before
baseline
Last week of
active treatment
Last week of
placebo treatment
n Z 24 n Z 22 n Z 23
10 (41.7%) 5 (22.7%) 10 (43.5%)
8 (33.3%) 3 (13.6%) 7 (30.4%)
4 (16.7%) 0 1 (4.3%)
3 (12.5%) 0 1 (4.3%)
0 0 1 (4.3%)
4 (16.7%) 1 (4.5%) 2 (8.7%)
2 (8.3%) 0 2 (8.7%)
1 (4.2%) 0 2 (8.7%)
1 (4.2%) 0 0
0 0 0
0 0 1 (4.3%)
1 (4.2%) 2 (9.1%) 0
0 0 0
1 (4.2%) 0 2 (8.7%)
Reduction of chronic cough 35still unclear [26]. Similarly, there is limited data on sys-
temic exposure following topical administration of
capsaicin-containing medical products.
The use of chilli peppers in food varies greatly between
different parts of the world. The daily intake of 1.6 mg of
capsaicin in the current study could be exceeded many
times in countries such as Mexico and Thailand, but it does
not reach that level in most Western countries [26].
Whether the prevalence of chronic unexplained cough is
lower in parts of the world with a high consumption of chilli
peppers is not known. In the clinic, we have met a handful
of patients claiming their cough improved after changing to
a very spicy diet. However, when we tried to recommend
this method to similar patients, it was not very successful
due to the side effects, such as stinging and irritation of the
mouth and throat. Such effects made it difficult for the
patients to adopt a spicy diet. The present findings indicate
improvement of cough from treatment with capsaicin, but a
lack of a prolonged effect on cough symptoms and capsaicin
cough sensitivity. This is consistent with our clinical expe-
rience that spicy food in some cough patients improved
cough but did not cure it as coughing returned when the
patients reverted to their more normal/less spicy diet.
The present results contradict earlier findings in elderly
patients with impairment of upper respiratory protective
reflexes after taking capsaicin orally [39]. In this group of
patients, daily capsaicin supplementation resulted in a
significant improvement in airway protective reflexes and
cough reflex sensitivity, particularly in patients with a high
risk for aspiration. We hypothesize that when the cough
reflex is impaired due to age or other causes, there are not
enough neuropeptides in the sensory nerve endings to
deplete and stimulate a cough protective reaction. On the
other hand, when the cough reflex is upregulated and easily
triggered by irritant stimuli, a regular supplement of
capsaicin may deplete some amount of signal substances in
sensory nerve endings and thereby reduce sensitivity.
In the medical community, the way chronic unexplained
cough is regarded seems to change over time. A new
paradigm, the cough hypersensitivity syndrome, has been
developed, which includes both patients with general
cough hypersensitivity towards, for example, environ-
mental irritants, and those with cough in combination with
symptoms that may indicate a reflux disease [12,40]. In a
recent report, there was a high degree of agreement among
opinion leaders as to the concept that cough hypersensi-
tivity underlies the aetiology of chronic cough in the ma-
jority of patients [14]. In some patients, while gastro-
oesophageal reflux undoubtedly contributes to chronic
cough, a large group of chronic cough patients claiming
symptoms that could be interpreted as reflux-related did
not have any pH changes nor did they experience a reduc-
tion in cough symptoms from proton pump inhibitors
[41,42]. Furthermore, the close connection between cough
and laryngeal sensory neuropathy has become increasingly
evident in recent years and has demonstrated treatment
pathways using non-pharmacological therapies [13,43,44].
Regarding cough as a neuropathic disorder with “upregu-
lated” sensitivity of both the respiratory and the gastroin-
testinal tract has changed earlier paradigms of chronic
cough and may increase the possibilities of developing new,
more effective antitussives [13,45]. The neuropathicdisorder view is further supported by earlier findings of
augmented TRPV1 expression in chronic cough [46].
There are some methodological weaknesses in our study
that must be discussed and improved in future research
regarding desensitized cough reflex from the intake of
capsaicin. First, as the number of participants was small,
larger groups of both patients and control subjects should
be studied to confirm the results. The lack of significant
improvement of C5 (pZ 0.0063 for the patient group) when
comparing the differences in cough thresholds after the use
of either a placebo or active substance is probably due to
the small number of participants included. Our power
calculation revealed that 22 included patients only ac-
quired a power of 50% and that our study should have
comprised 41 patients to reach the power of 0.80. A
“washout” period between the exchange of the active
substance and the placebo would have strengthened the
interpretations. It would probably have been possible to
give higher concentrations of capsaicin in light of the few
side effects. Thus, this could be considered for future
research. To follow up the patients once a week with regard
to symptoms and capsaicin cough sensitivity would have
provided more specific information regarding the time
needed to achieve an effect. Furthermore, it would have
been beneficial to use a cough-specific questionnaire such
as the Leicester Cough Questionnaire, but, unfortunately,
there is no such questionnaire translated into Swedish. The
Hull questionnaire was designed for reflux cough, which
may limit its value, and the Swedish version of the Hull
cough questionnaire is not validated, though such studies
are in progress. Furthermore, using a cough monitor at
home, at least during some parts of the study, would have
provided more objective information about the daily cough
problems of patients. Future studies should also include
measuring the capsaicin plasma concentrations as well as
study capsaicin metabolism. Furthermore, there is the need
for a more thorough examination of participants that in-
cludes nitric oxide levels, nasal sinus CT scan, pH-metry and
echocardiogram to exclude any other possible reasons for
coughing. To only include patients who had never been
smokers would also be an advantage.
We conclude that, despite the above-mentioned weak-
nesses, our study presents new and interesting findings in
concordance with the theory of chronic cough as a neuro-
pathic disorder, and it indicates the possibility of
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